Drug Profile
Research programme: cyclin-dependent kinase inhibitors - Johnson & Johnson
Alternative Names: JNJ 7706621; triazine-pyridine biheteroaryl series - Johnson & JohnsonLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Sep 2007 Information from the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the introduction
- 19 Sep 2005 Data presented at the 230th American Chemical Society National Meeting - (230th-ACS-2005) have been added to the Cancer pharmacodynamics section